[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pneumonia\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pneumonia":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,121,0,25,[9,46,83,133,160,185,213,241,253,286,312,338,362,386,414,436,457,488,506,529,548,567,594,620,646],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":4},"100053455","phase-4-the-lalelalung-study-digital-stethoscope-clinical-evaluation-100053455",false,"NCT07631377","The LalelaLung Study: Digital Stethoscope Clinical Evaluation","LaLeLa","Inclusion Criteria:\n\n* Age 2 to 59 months at the time of screening\n* Presence of cough and\u002For difficulty breathing\n* No WHO-defined emergency\u002Fdanger signs (e.g., grunting, cyanosis, apnea, convulsions, or altered level of consciousness)\n* A legal caregiver is present, able to understand the study information, and willing to provide written informed consent\n* Caregiver is willing and able to provide contact information (e.g., mobile phone number) to allow 7-day follow-up after the clinic visit\n\nExclusion Criteria:\n\n* Presence of WHO-defined emergency signs requiring immediate referral or hospital admission (grunting, cyanosis, apnea, uncompensated shock, convulsions, diarrhea with severe dehydration, or altered level of consciousness)\n* Critical illness or clinical instability judged by the screening clinician or study physician to require urgent medical attention\n* Age outside the target range (younger than 2 months or older than 59 months)\n* Previous enrollment in the study\n* Refusal or withdrawal of informed consent by the legal caregiver at any time prior to randomization","ALL","2 Months","59 Months",{"count":21,"type":22},350,"ESTIMATED","INTERVENTIONAL",[25],"PHASE4","Pneumonia is the leading infectious cause of death in children under five years of age worldwide, and most of these deaths occur in low- and middle-income countries. In these settings, frontline health workers diagnose pneumonia using the World Health Organization's Integrated Management of Childhood Illness (IMCI) guidelines, which rely mainly on counting how fast a child is breathing and checking for chest indrawing. This approach has saved many lives, but it is not very specific. As a result, many children who actually have self-limiting viral illnesses that do not require antibiotics are nonetheless treated with antibiotics, contributing to the global rise of antimicrobial resistance.\n\nNew digital stethoscopes paired with artificial intelligence (AI) can record a child's lung sounds and automatically detect abnormal sounds such as crackles and wheezes with accuracy comparable to physicians. The LaLeLa Lung Study will evaluate whether adding an AI-enabled digital stethoscope to standard IMCI assessment improves the accuracy of pneumonia diagnosis among children aged 2 to 59 months who present with cough and\u002For difficult breathing at a primary care clinic in Cape Town, South Africa.\n\nThe main component (Objective 1) is a randomized, triple-blinded diagnostic accuracy study that will enroll 350 children, randomly assigned in a 1:1 ratio to either IMCI care enhanced by the AI-enabled digital stethoscope or standard IMCI care. An independent panel of physicians, blinded to the AI results and to study-arm assignment, will review each case and serve as the reference standard for determining whether pneumonia was truly present. The investigators hypothesize that IMCI enhanced by the AI stethoscope will diagnose pneumonia more accurately, and target antibiotics more appropriately, than standard IMCI alone. Nested sub-studies will additionally evaluate a second AI stethoscope for tuberculosis detection, a wearable lung-sound and respiratory-rate patch, an automated respiratory-rate monitor, and a smartphone-connected pulse oximeter.\n\nA separate component (Objective 2) is a mixed-methods implementation study at a second clinic that will assess how easily health workers can use these devices, how acceptable the devices are to health workers and caregivers, and how well the devices fit into routine clinic workflows.\n\nThroughout the study, all AI-generated results will remain concealed from clinic staff, study clinicians, and caregivers, so the AI-generated results will not influence the care any child receives. All children continue to receive standard IMCI care. Findings will help inform whether AI-enabled digital auscultation should be integrated into childhood pneumonia care in South Africa and similar low-resource settings, with the goal of improving diagnosis, strengthening antibiotic stewardship, and reducing antimicrobial resistance and child mortality.",[28,29,30,31,32,33],"Pneumonia","Tuberculosis, Pulmonary","Respiratory Tract Infections","Bronchiolitis","Respiratory Sounds","Antibiotic Resistant Strain","NOT_YET_RECRUITING","2026-07-10",{"date":37,"type":38},"2026-07-13","ACTUAL",{"date":40,"type":22},"2026-08-17",{"date":42,"type":22},"2028-06-30",{"name":44,"class":45},"Johns Hopkins University","OTHER",{"id":47,"slug":48,"hasResults":12,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":52,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":4,"leadSponsor":79,"locationsCount":82},"100058416","natural-history-management-and-genetics-of-the-hyperimmunoglobulin-e-recurrent-infection-syndrome-hies-100058416","NCT00006150","Natural History, Management, and Genetics of the Hyperimmunoglobulin E Recurrent Infection Syndrome (HIES)","* INCLUSION CRITERIA:\n\nPatients may be included in this study who:\n\n* Were referred to the NIH with a diagnosis or a suspicion of Hyper IgE syndrome.\n* Are patients referred for other immune syndromes that demonstrate some of the characteristics of HIES.\n\n  * \\>=1 month for affected subjects\n  * Aged \\>=2 years for unaffected subjects\n* For unaffected subjects, are able to understand and have the willingness to sign a written informed consent document.\n\nUnaffected biological relatives of HIES patients are also eligible to enroll in a separate relative cohort.\n\nEXCLUSION CRITERIA:\n\nCoronary CTA will not be performed on any patient younger than 30 years or with contraindication to IV contrast media. This includes patients with 1) creatinine value of \\>1.3 mg\u002FdL, 2) history of multiple myeloma, 3) Use of metformin-containing products less than 24 hours prior to contrast media, and 4) history of significant allergic reaction to CT contrast agents despite the use of premedication.\n\nSubjects with a medical, psychiatric, or social condition which, in the opinion of the investigator, would place undue burden on the subject, NIH resources, or increase risk of participation, may be excluded.",true,"1 Month","120 Years",{"count":56,"type":22},600,"OBSERVATIONAL","The Hyper IgE Syndromes (HIES) are primary immunodeficiencies resulting in eczema and recurrent skin and lung infections. Autosomal dominant Hyper IgE syndrome (AD-HIIES; Job's syndrome) is caused by STAT3 mutations, and is a multi-system disorder with skeletal, vascular, and connective tissue manifestations. Understanding how STAT3 mutations cause these diverse clinical manifestations is critical to our complete understanding of bone metabolism, bronchiectasis, dental maturation, and atherosclerosis. Bi-allelic mutations in DOCK8 cause a combined immunodeficiency previously described as autosomal-recessive Hyper IgE syndrome. These individuals suffer from extensive viral infections as well as have a high incidence of malignancy and mortality. The pathogenesis of this disease and long-term natural history is being investigated. Therefore, we seek to enroll patients and families with a confirmed or suspected diagnosis of HIES syndrome for extensive phenotypic and genotypic study as well as disease management. Patients will be carefully examined by a multidisciplinary team and followed longitudinally. Through these studies we hope to better characterize the clinical presentation of STAT3-mutated HIES, DOCK8 deficiency and other causes of the hyper IgE phenotype, and to be able to identify further genetic etiologies, as well as understand the pathogenesis of HIES. We seek to enroll 300 patients and 300 relatives....",[60,28,61,62,63],"Infections","Immune System Diseases","STAT3 Transcription Factor","Job Syndrome",[65,66,67,68,69,70,71,72],"DOCK8 Deficiency","PGM3 Deficiency","STAT3 Mutation","Job's Syndrome","Immunodeficiency","Natural History","Hyperimmunologobulin E Syndrome","HIE Syndrome","RECRUITING","2026-06-27",{"date":76,"type":38},"2026-06-30",{"date":78,"type":38},"2000-08-10",{"name":80,"class":81},"National Institute of Allergy and Infectious Diseases (NIAID)","NIH",1,{"id":84,"slug":85,"hasResults":12,"nctId":86,"briefTitle":87,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":91,"enrollmentInfo":92,"targetDuration":94,"studyType":57,"phases":4,"briefSummary":95,"conditions":96,"keywords":106,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":124,"lastUpdatePostDateStruct":125,"startDateStruct":127,"completionDateStruct":129,"leadSponsor":131,"locationsCount":82},"100645390","derivation-and-validation-of-the-fungal-pneumonia-assessment-and-likelihood-predictor-score-100645390","NCT07681583","Derivation and Validation of the Fungal Pneumonia Assessment and Likelihood Predictor Score","FUNGAL-P","Inclusion Criteria:\n\n* Age ≥18 years and ≤90 years.\n* Presentation to the Emergency Department or hospital with pneumonia.\n* Pneumonia defined according to IDSA\u002FATS criteria as the presence of at least two clinical signs or symptoms of lower respiratory tract infection (temperature \\\u003C36.0°C or \\>38.0°C, respiratory rate \\>20 breaths\u002Fmin, oxygen saturation \\\u003C90% on room air, arterial PaO₂ \\\u003C60 mmHg, cough, sputum production, white blood cell count \\\u003C4,000\u002FμL or \\>10,000\u002FμL, or bandemia \\>10%) together with radiographic evidence of a new pulmonary infiltrate or cavitary lesion.\n* Bronchoalveolar lavage (BAL), bronchial aspirate (BAS), or endotracheal aspirate (ETA) performed within 48 hours of hospital presentation.\n* Modified Rankin Scale score \\\u003C5.\n* Availability of microbiological investigations for identification of fungal, bacterial, or viral pathogens.\n* Provision of informed consent, when required by applicable regulations and ethics committee approval.\n\nExclusion Criteria:\n\n* Refusal or withdrawal of informed consent.\n* Age \\\u003C18 years or \\>90 years.\n* Pregnancy.\n* Expected life expectancy \\\u003C3 months.\n* Hospital-acquired pneumonia with onset \\>48 hours after hospital admission.\n* Modified Rankin Scale score ≥5.\n* Absence of microbiological diagnostic evaluation.\n* No identified bacterial, fungal, or viral pathogen after microbiological investigations.","18 Years","90 Years",{"count":93,"type":22},400,"30 Days","The FUNGAL-P study is a single-center observational study designed to derive and validate a clinical prediction score for the early identification of fungal pneumonia in adult patients presenting with pneumonia.\n\nThe study includes a retrospective derivation cohort and a prospective validation cohort of patients undergoing microbiological evaluation of lower respiratory tract samples. Clinical, laboratory, radiological, microbiological, and treatment-related variables associated with fungal pneumonia will be analyzed to identify independent predictors of fungal infection. These predictors will be combined to develop the FUNGAL-P score.\n\nThe derived score will subsequently be evaluated in a prospective validation cohort to assess its diagnostic performance, calibration, and clinical utility. The ultimate goal is to facilitate earlier recognition of fungal pneumonia and support timely diagnostic testing and antifungal treatment in patients presenting to the Emergency Department or hospital with pneumonia.",[28,97,98,99,100,101,102,103,104,105],"Fungal Pneumonia","Aspergillosis Pneumonia","Pulmonary Aspergillosis","Pulmonary Aspergillosis Invasive","Pneumocystis","Pneumocystis Pneumonia","Fungal Disease","Fungal Infection","Fungal Infection Lungs",[97,107,99,108,102,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123],"Aspergillus","Pneumocystis jirovecii","Coinfection","Community-Acquired Pneumonia","CAP","Risk Prediction","Clinical Prediction Rule","Clinical Risk Score","FUNGAL-P Score","SCORE","Bronchoalveolar Lavage","Emergency Department","Internal medicine","Infectious disease","Diagnostic Accuracy","Risk Factors","Respiratory Infection","2026-06-26",{"date":126,"type":38},"2026-07-02",{"date":128,"type":38},"2025-11-13",{"date":130,"type":22},"2031-11-13",{"name":132,"class":45},"Azienda Ospedaliero-Universitaria Careggi",{"id":134,"slug":135,"hasResults":12,"nctId":136,"briefTitle":137,"officialTitle":138,"acronym":4,"eligibilityCriteria":139,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":23,"phases":142,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":150,"lastUpdatePostDateStruct":151,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":159},"100637440","phase-2-a-clinical-trial-to-evaluate-agent-797-plus-standard-of-care-in-participants-with-severe-pneumonia-with-moderate-to-severe-acute-hypoxemic-respiratory-failure-100637440","NCT07615010","A Clinical Trial to Evaluate agenT-797 Plus Standard of Care in Participants With Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure","Phase 2 Adaptive Randomized, Placebo -Controlled Trial of agenT-797 + Standard of Care Vs. Placebo + Standard of Care in Severe Pneumonia With Moderate to Severe Acute Hypoxemic Respiratory Failure (AHRF) By Global ARDS Criteria","Key Inclusion Criteria:\n\n* Admission to an intensive care unit (ICU) with severe pneumonia of any etiology (viral, bacterial, fungal, or mixed), with and without trauma based on clinical suspicion\n* Acute hypoxemic respiratory failure (AHRF)\n* Evidence of moderate to severe acute respiratory distress syndrome (ARDS) based on Global ARDS criteria\n* Onset of severe pneumonia with AHRF ≤7 days prior to informed consent\n\nKey Exclusion Criteria:\n\n* More than two vasopressors to maintain a mean arterial pressure ≥65 millimeters of mercury at the time of informed consent\n* Pregnancy or breastfeeding\n* History of cytokine release syndrome, as documented in the medical record or reported by the participant, legally authorized representative, or close relative\n* Current participation in another interventional clinical trial, or receipt of an investigational medicinal product within 30 days prior to screening, unless reviewed and approved in writing by the medical monitor\n\nNote: Other protocol-defined inclusion\u002Fexclusion criteria may apply.",{"count":141,"type":22},90,[143],"PHASE2","This clinical trial will evaluate the efficacy and safety of a single intravenous dose of agenT-797 administered in addition to standard of care (SOC), compared with placebo plus SOC, in reducing short-term mortality in adult participants with severe pneumonia and moderate to severe AHRF. All participants will receive SOC management for severe pneumonia and acute respiratory distress syndrome (ARDS).",[28],[147,148,149],"Acute Hypoxemic Respiratory Failure","AHRF","agenT-797","2026-06-25",{"date":124,"type":38},{"date":153,"type":38},"2026-05-26",{"date":155,"type":22},"2027-08",{"name":157,"class":158},"MiNK Therapeutics","INDUSTRY",4,{"id":161,"slug":162,"hasResults":12,"nctId":163,"briefTitle":164,"officialTitle":164,"acronym":4,"eligibilityCriteria":165,"healthyVolunteers":12,"sex":17,"minAge":166,"maxAge":4,"enrollmentInfo":167,"targetDuration":4,"studyType":23,"phases":169,"briefSummary":171,"conditions":172,"keywords":173,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":183,"locationsCount":82},"100616659","ketogenic-approach-to-restore-muscle-in-older-patients-with-community-acquired-pneumonia---karma-p-trial-100616659","NCT07308483","Ketogenic Approach to Restore Muscle in Older Patients With Community-Acquired Pneumonia - KARMA-P Trial","Inclusion Criteria:\n\n* Age 55 years and older\n* Bacterial community-acquired pneumonia\n* Expected at least 10-day stay in the hospital\n* Ability to ingest food orally\n* Willingness to be randomized to either treatment group\n* Willingness to participate in all study procedures\n\nExclusion Criteria:\n\n* Failure to provide informed consent\n* Moribund\n* Vegetarian\u002Fvegan\n* Severe cardiac disease, including NYHA Class III or IV congestive heart failure, clinically significant aortic stenosis, history of cardiac arrest, use of a cardiac defibrillator, or uncontrolled angina\n* Diagnosed dementia\n* Hip fracture, hip or knee replacement, or spinal surgery within past 4 months\n* Simultaneous participation in another intervention trial","55 Years",{"count":168,"type":22},30,[170],"NA","The purpose of the study is to see if a ketogenic diet compared to a standard diet is better to maintain muscle function and health in hospital admitted pneumonia patients.",[28],[174,175],"ketogenic feeding","pneumonia","2026-06-22",{"date":178,"type":38},"2026-06-24",{"date":180,"type":22},"2026-10-01",{"date":182,"type":22},"2029-07-31",{"name":184,"class":45},"University of Alabama at Birmingham",{"id":186,"slug":187,"hasResults":12,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":4,"eligibilityCriteria":191,"healthyVolunteers":12,"sex":17,"minAge":192,"maxAge":193,"enrollmentInfo":194,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":196,"conditions":197,"keywords":200,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":207,"lastUpdatePostDateStruct":208,"startDateStruct":209,"completionDateStruct":4,"leadSponsor":211,"locationsCount":82},"100063668","study-of-lung-proteins-in-patients-with-pneumonia-100063668","NCT00077909","Study of Lung Proteins in Patients With Pneumonia","Biomarkers and Protein Mass Expression Profiles in Bronchoalveolar Lavage From Patients With Lung Infiltrates","* INCLUSION CRITERIA:\n* All eligible patients undergoing diagnostic bronchoscopy who provide consent for proteomic analysis of BAL fluid supernatant and chart review of patient characteristics will be included in this study.\n* A parent\u002Fguardian may provide consent for a child age 17 or under and a Legally Authorized Representative (LAR) may provide consent for adults unable to consent.\n\nEXCLUSION CRITERIA:\n\nPatients undergoing bronchoscopy but not wanting to participate with either the chart review or the proteomic analysis of BAL fluid supernatant will be excluded.","3 Years","99 Years",{"count":195,"type":22},750,"This study will examine the different types of proteins present in the lungs of patients with pneumonia to explore the causes of different types of the disease. Pneumonia is a condition that causes lung inflammation AND is often caused by an infection. It is usually diagnosed by lung x-rays and listening to the chest with a stethoscope. This method can diagnose pneumonia, but it does not provide information on the cause of the inflammation - information that might be helpful in guiding treatment. This study will measure proteins in the lungs of patients to see if certain proteins are associated with specific forms of pneumonia, and can thus serve as biomarkers for disease.\n\nPatients undergoing diagnostic bronchoscopy at the NIH Clinical Center may participate in this study. Patients will undergo bronchoscopy and bronchoalveolar lavage as scheduled for their medical care. For this procedure, the patient's mouth and throat are numbed with lidocaine; a sedative may be given for comfort. A thin flexible tube called a bronchoscope is advanced through the nose or mouth into the lung airways to examine the airways carefully. Saline (salt water) is then injected through the bronchoscope into the air passage, acting as a rinse. A sample of fluid is then withdrawn for microscopic examination. Researchers in the current study will use some of the fluid obtained from the lavage to examine for protein content.\n\nIn addition to the bronchoscopy and bronchoalveolar lavage, participants will have about 2 tablespoons of blood drawn to compare blood test results with the results of the lung washings. Patients' medical records will be reviewed to obtain information on past medical history, current medical treatment, vital signs, and results of x-ray tests.",[28,198,199],"Pulmonary Disease","Lung Disease",[201,202,28,203,204,70,205,198,206],"Proteomics","Infection","Mass Spectrometry","BAL","Lung","Lung Infiltrates","2026-06-18",{"date":176,"type":38},{"date":210,"type":38},"2004-02-20",{"name":212,"class":81},"National Institutes of Health Clinical Center (CC)",{"id":214,"slug":215,"hasResults":12,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":23,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":240},"100642234","self-directed-mobile-mindfulness-to-address-icu-survivors-psychological-distress-100642234","NCT07634419","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress","Self-directed Mobile Mindfulness to Address ICU Survivors' Psychological Distress: Lift RCT (Lift 3)","Lift 3","Inclusion Criteria:\n\nInclusion criteria present during hospitalization\n\n1. Adult (age ≥18)\n2. Managed in an ICU for ≥24 hours during the time inclusion criterion #3 is met\n3. Serious acute cardiorespiratory condition, defined as ≥1 of the following:\n\n   * mechanical ventilation via endotracheal tube for ≥4 hours\n   * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure\n   * new use of supplemental oxygen ≥6 liters per minute (or increase in baseline continuous oxygen)\n   * use of vasopressors for shock of any etiology\n   * use of inotropes for shock of any etiology\n   * use of pulmonary vasodilators\n   * use of aortic balloon pump or cardiac assist device for cardiogenic shock\n   * use of diuretic intravenous drip\n   * evidence of acute coronary ischemia (i.e., elevated troponin level, supporting EKG changes, unstable angina symptoms documented)\n   * urgent cardiac catheterization\n4. Cognitive status intact\n\n   o No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart\n5. Absence of severe and\u002For persistent mental illness\n\n   o Treatment for severe and\u002For persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \\[as per medical record\\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission\n6. Functional fluency in English or Spanish (i.e., sufficient knowledge of English or Spanish to complete study tasks like watch videos, complete surveys)\n\nInclusion criteria present after hospital discharge (i.e., at the time of arrival home after discharge from the hospital):\n\n1\\. Elevated baseline psychological distress symptoms, defined as a PHQ-9 score ≥5\n\nExclusion Criteria:\n\nExclusion criteria present in the hospital:\n\n1\\. Discharged to a location other than a home setting (e.g., nursing home, long-term acute care facility, inpatient rehabilitation facility)\n\nExclusion criteria present after hospital discharge (i.e., at T1 Data Collection conducted at the time of arrival home from the hospital):\n\n1. Severe psychological distress as assessed by endorsement of active suicidality (see Protection of Human Subjects document for study team management of this finding)\n2. Failure to randomize within 1 month after discharge from the hospital to home\n3. Failure to login to study app and access content within 2 weeks after randomization",{"count":222,"type":22},450,[170],"Serious acute heart and lung illnesses like heart failure, severe COVID, and sepsis often leave survivors struggling not only physically, but also with lasting depression, anxiety, and stress. These problems that are hard to treat because access to mental health care is often limited. To help address this, the researchers created Lift, a fully automated mindfulness program designed with patient input and delivered through a mobile app. The investigators now plan a large, multi-site study to test whether Lift improves mental health and quality of life over six months compared to a critical illness education program called Enlighten Recovery. Overall the goal is to make an easy-to-use, widely accessible program available to people across the U.S., including those who speak Spanish.",[226,227,228,229,28,230],"Critical Illness","Heart Failure","Sepsis","Ards","Trauma Injury","2026-06-12",{"date":233,"type":38},"2026-06-16",{"date":235,"type":22},"2026-06-01",{"date":237,"type":22},"2031-05-31",{"name":239,"class":45},"Duke University",3,{"id":242,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":243,"targetDuration":4,"studyType":23,"phases":244,"briefSummary":26,"conditions":245,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":252,"locationsCount":4},"100643415",{"count":21,"type":22},[25],[28,29,30,31,32,33],"2026-06-05",{"date":248,"type":38},"2026-06-09",{"date":250,"type":22},"2026-07-20",{"date":42,"type":22},{"name":44,"class":45},{"id":254,"slug":255,"hasResults":12,"nctId":256,"briefTitle":257,"officialTitle":257,"acronym":4,"eligibilityCriteria":258,"healthyVolunteers":12,"sex":17,"minAge":259,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":23,"phases":262,"briefSummary":264,"conditions":265,"keywords":268,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":285},"100633704","phase-3-comparative-efficacy-and-safety-of-propofol-ketamine-combination-versus-propofol-monotherapy-in-geriatric-patients-under-invasive-ventilation-100633704","NCT07530146","Comparative Efficacy and Safety of Propofol-Ketamine Combination Versus Propofol Monotherapy in Geriatric Patients Under Invasive Ventilation","Inclusion Criteria:\n\n* Age ≥ 65 years\n* Admitted to ICU with a diagnosis of infection (sepsis, septic shock, or pneumonia)\n* Known history of cardiac disease (e.g., ischemic heart disease, heart failure, arrhythmias)\n* Requiring endotracheal intubation for airway protection or respiratory failure\n* Informed consent obtained from patient or legal representative\n* Patient NOT on sedation prior randomization.\n\nExclusion Criteria:\n\n* Known allergy or contraindication to propofol or ketamine\n* Severe hepatic or renal dysfunction (Child-Pugh C, eGFR \\\u003C 30 mL\u002Fmin\u002F1.73m²)\n* Uncontrolled hypertension (SBP \\> 180 mmHg or DBP \\> 110 mmHg)\n* Intracranial pathology (e.g., raised intracranial pressure, recent stroke, brain tumor)\n* Ongoing use of other sedative or anesthetic agents within 12 hours prior to intubation\n* Do-not-intubate or do-not-resuscitate orders\n* Participation in another interventional trial within the last 30 days\n* History of Psychosis\n* Severe Organ Dysfunction: Patients with Child-Pugh C hepatic failure\n* • Severe hypotension despite vasopressor therapy (systolic blood pressure \\\u003C 100 mmHg or diastolic blood pressure \\\u003C 70 mmHg)","65 Years",{"count":261,"type":22},41,[263],"PHASE3","The study is a prospective randomized controlled trial comparing the efficacy and safety of propofol-ketamine (\"Ketofol\") versus propofol monotherapy in geriatric ICU patients. Eligible participants are critically ill elderly patients with a history of cardiac disease who require endotracheal intubation and have not yet received sedation. The investigators focus on a specific population in which geriatric patients have different pharmacokinetics and pharmacodynamics and are more prone to side effects than other populations.\n\nPrimary outcome: Incidence of hemodynamic instability (defined as hypotension requiring vasopressors), measured by mean arterial pressure (MAP) at baseline, during intubation, and post-intubation at 1, 3, 5, 10, 20, 30, and 60 minutes, then hourly for 24 hours.",[266,267,28],"The Critically Ill Patient is Requiring Intubation","Septic Shock",[269,270,271,175,272,273,274,275,276],"ketofol","propofol","septic shock","geriatric","elderly","critical ill","ICU patient","intubation","2026-05-28",{"date":235,"type":38},{"date":280,"type":22},"2026-04",{"date":282,"type":22},"2026-10",{"name":284,"class":45},"Helwan University",2,{"id":287,"slug":288,"hasResults":12,"nctId":289,"briefTitle":290,"officialTitle":291,"acronym":4,"eligibilityCriteria":292,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":293,"enrollmentInfo":294,"targetDuration":4,"studyType":23,"phases":296,"briefSummary":298,"conditions":299,"keywords":300,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":304,"lastUpdatePostDateStruct":305,"startDateStruct":307,"completionDateStruct":308,"leadSponsor":310,"locationsCount":159},"100637274","early-phase-1-yiqi-huoxue-jiedu-formula-combined-with-bacteriophages-in-the-treatment-of-severe-pneumonia-100637274","NCT07612605","Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia","A Randomized Controlled Trial (RCT) of Yiqi Huoxue Jiedu Formula Combined With Bacteriophages in the Treatment of Severe Pneumonia Caused by Drug-resistant Gram-negative Bacilli","Inclusion Criteria:\n\n* Patients who meet the diagnostic criteria for severe pneumonia caused by drug-resistant Gram-negative bacilli and conform to the TCM syndrome differentiation of Qi deficiency, toxin accumulation and blood stasis syndrome;\n* Patients confirmed by rapid on-site microbiological evaluation (M-ROSE), clinical microbial culture and drug susceptibility testing (based on the drug susceptibility test results of our hospital or other Grade A tertiary hospitals) to be infected with multidrug-resistant Klebsiella pneumoniae, Acinetobacter baumannii or Pseudomonas aeruginosa;\n* Aged 18 to 85 years old;\n* Patients or their family members agree to cooperate with the collection of upper and lower respiratory tract specimens, consent to bronchoscopy plus bronchoalveolar lavage, and agree to receive nebulized inhalation of bacteriophage therapy;\n* Patients or their family members have fully read, understood and signed the informed consent form.\n\nExclusion Criteria:\n\n* Women who are pregnant or lactating;\n* Patients with immunodeficiency;\n* Patients receiving immunosuppressive therapy or suffering from immunodeficiency diseases;\n* Patients who have received mechanical ventilation for more than 60 days prior to enrollment;\n* Patients with active pulmonary tuberculosis, lung abscess, or Grade D chronic obstructive pulmonary disease (COPD);\n* Patients with incomplete sampling or clinical data;\n* Patients with known allergies to bacteriophage products or the components of Yiqi Huoxue Jiedu Formula;\n* Patients judged by the researchers as unsuitable for participation in this study.","85 Years",{"count":295,"type":22},250,[297],"EARLY_PHASE1","Through a prospective randomized controlled trial, we systematically evaluate the effects of Yiqi Huoxue Jiedu Formula combined with bacteriophage therapy on the bacterial clearance rate, disease improvement rate and mortality rate in patients with severe pneumonia caused by drug-resistant bacteria, so as to clarify its clinical transformation value.",[28],[301,302,303,28],"bacteriophage","Yiqi Huoxue Jiedu Formula","drug-resistant bacteria","2026-05-21",{"date":306,"type":38},"2026-05-29",{"date":235,"type":22},{"date":309,"type":22},"2029-12-31",{"name":311,"class":45},"Chinese PLA General Hospital",{"id":313,"slug":314,"hasResults":12,"nctId":315,"briefTitle":316,"officialTitle":317,"acronym":318,"eligibilityCriteria":319,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":320,"targetDuration":4,"studyType":23,"phases":322,"briefSummary":323,"conditions":324,"keywords":325,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":329,"lastUpdatePostDateStruct":330,"startDateStruct":332,"completionDateStruct":334,"leadSponsor":336,"locationsCount":82},"100589121","early-phase-1-ino300-therapy-in-critically-ill-patients-with-pneumonia-100589121","NCT06950294","iNO300 Therapy in Critically Ill Patients With Pneumonia","High Dose Inhaled Nitric Oxide Therapy in Critically Ill Patients With Pneumonia: a Pilot, Double-blinded, Randomized, Controlled Trial","iNO300","Inclusion Criteria:\n\n* 18 years or older\n* Intubated and mechanically ventilated\n* Within 72h of diagnosis of community- or hospital-acquired pneumonia\n* Written informed consent obtained from patients or legally authorized representatives\n\nExclusion Criteria:\n\n* Baseline methemoglobin 3% or higher\n* Genetic diseases including glucose-6-phosphate dehydrogenase deficiency, cytochrome b5 reductase deficiency, sickle cell disease\n* Oxygen saturation \\\u003C 88% on 100% inspired fraction of oxygen\n* Anemia with hemoglobin \\\u003C 7.0 g\u002Fdl\n* Acute cardiogenic shock requiring inotropic or mechanical support with an ejection fraction less than 20%\n* Receiving inhaled NO therapy or decision to initiate inhaled NO therapy within 24 hours post randomization\n* A decision to do-not-resuscitate (DNR)\n* Enrollment in another experimental antimicrobial treatment protocol\n* Patients for whom follow-up is expected to be impossible",{"count":321,"type":22},34,[297],"The goal of this clinical trial is to learn the formation and recovery rate of methemoglobin (MetHb) in severely sick patients with pneumonia who receive high doses of inhaled nitric oxide (iNO) therapy at 250 parts per million (ppm), not exceeding 300 ppm. Meanwhile, the benefits of the therapy to treat severely sick patients with pneumonia will be explored. Patients who are 18 years or older, newly diagnosed with pneumonia, and severely sick with requirement of a breathing machine could be included. The main questions it aims to answer are:\n\nHow does methemoglobin change through the iNO treatment? Does iNO therapy increase the number of patients recovering from pneumonia? Researchers will compare iNO treatment to placebo, which means using the same device as the treatment group without delivering the study drug.\n\nParticipants will:\n\n* Receive iNO treatment starting at 250 ppm, not exceeding 300 ppm, 40 min, every 6 hours, from day 1 to day 5\n* Be followed up for 60 days",[226,28],[326,28,327,328],"High dose inhaled nitric oxide","Critical care","Methemoglobin","2026-05-20",{"date":331,"type":38},"2026-05-22",{"date":333,"type":38},"2026-02-23",{"date":335,"type":22},"2026-12",{"name":337,"class":45},"Massachusetts General Hospital",{"id":339,"slug":340,"hasResults":12,"nctId":341,"briefTitle":342,"officialTitle":343,"acronym":344,"eligibilityCriteria":345,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":346,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":348,"conditions":349,"keywords":352,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":356,"completionDateStruct":358,"leadSponsor":360,"locationsCount":82},"100637503","sulbactam-durlobactam-in-crab-infection-a-real-world-cohort-study-100637503","NCT07601711","Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study","This is a Single-center Real-world Observational Cohort Study of Sulbactam-Durlobactam for Carbapenem-Resistant Acinetobacter Baumannii Infections: Effectiveness, Safety, and Exposure-Response Analysis","SD-CRAB","Inclusion Criteria:\n\n* Age ≥18 years.\n* Hospitalized patients receiving anti-CRAB antimicrobial therapy, including:\n\n  1. patients with confirmed carbapenem-resistant Acinetobacter baumannii (CRAB) infection based on microbiological testing in combination with clinical evidence of infection; or\n  2. transplant recipients with donor-derived CRAB colonization or infection who receive early targeted antimicrobial therapy.\n* Treatment initiation time can be clearly determined.\n* Availability of clinical outcome data.\n\nExclusion Criteria:\n\n* Colonization without evidence of active infection.\n* Missing key clinical data.\n* Inability to determine treatment initiation time.\n* Pregnancy or lactation.\n* Patients considered unsuitable by investigators.",{"count":347,"type":22},200,"This is a multicenter real-world observational cohort study designed to evaluate the effectiveness and safety of sulbactam-durlobactam in patients with carbapenem-resistant Acinetobacter baumannii (CRAB) infections. Patients receiving sulbactam-durlobactam will be compared with those receiving other anti-CRAB regimens during the same period.\n\nThe primary outcomes are 28-day all-cause mortality and clinical failure. Secondary outcomes include microbiological clearance, recurrence, length of hospital and ICU stay, duration of mechanical ventilation, and adverse events.\n\nTo reduce confounding inherent in observational studies, propensity score methods, including matching and inverse probability weighting, will be applied. A nested therapeutic drug monitoring (TDM) sub-cohort will be established to explore the relationship between drug exposure and clinical outcomes.",[350,351,28,228],"Carbapenem-Resistant Acinetobacter Baumannii Infection","Bloodstream Infection",[353],"CRAB Infection","2026-05-19",{"date":331,"type":38},{"date":357,"type":38},"2025-11-11",{"date":359,"type":22},"2027-11-11",{"name":361,"class":45},"Sichuan Provincial People's Hospital",{"id":363,"slug":364,"hasResults":12,"nctId":365,"briefTitle":366,"officialTitle":367,"acronym":4,"eligibilityCriteria":368,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":369,"targetDuration":4,"studyType":23,"phases":371,"briefSummary":372,"conditions":373,"keywords":374,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":379,"startDateStruct":380,"completionDateStruct":382,"leadSponsor":384,"locationsCount":82},"100627848","efficacy-and-safety-of-intrapulmonary-percussive-ventilation-in-patients-with-pulmonary-infection-receiving-invasive-mechanical-ventilation-100627848","NCT07453966","Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation","Efficacy and Safety of Intrapulmonary Percussive Ventilation in Patients With Pulmonary Infection Receiving Invasive Mechanical Ventilation Assessed by Electrical Impedance Tomography: a Randomized Controlled Trial","Inclusion Criteria:\n\n1. age ≥ 18 years;\n2. Meeting the diagnostic criteria for pulmonary infection, defined as follows: meeting the diagnostic criteria for hospital-acquired pneumonia and ventilator-associated pneumonia as defined in the Chinese Guidelines for the Diagnosis and Treatment of Hospital-Acquired Pneumonia and Ventilator-Associated Pneumonia in Adults, or meeting the diagnostic criteria for community-acquired pneumonia as defined in the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia in Adults; radiographic evidence of new or progressive pulmonary infiltrates plus at least two clinical criteria, including fever or hypothermia, leukocytosis or leukopenia, purulent respiratory secretions, or worsening oxygenation.\n3. Oxygenation index (PaO₂\u002FFiO₂) ≤ 300;\n4. Currently receiving invasive mechanical ventilation and expected to require mechanical ventilation for ≥ 5 days;\n5. Written informed consent provided by the patient's family member or legally authorized representative.\n\nExclusion Criteria:\n\n1. Presence of severe hemodynamic instability (norepinephrine dose \\> 0.5 μg\u002Fkg\u002Fmin);\n2. Markedly elevated intracranial pressure (\\> 25 mmHg) or a condition requiring strict intracranial pressure control;\n3. Severe pulmonary bullae or untreated tension pneumothorax or undrained mediastinal emphysema;\n4. Active massive hemoptysis;\n5. Severe bronchospasm with inability to tolerate fluctuations in airway pressure;\n6. Unstable chest wall, flail chest, recent thoracic surgery, or severe thoracic spine injury;\n7. Receiving extracorporeal membrane oxygenation (ECMO);\n8. Pregnant or breastfeeding women;\n9. Inability to place the EIT chest belt (e.g., open thoracic surgical wounds or skin lesions at the belt placement site);\n10. Concurrent participation in another clinical trial.",{"count":370,"type":22},96,[170],"The goal of this clinical trial is to learn whether adding intrapulmonary percussion ventilation (IPV) to standard airway clearance treatment improves clinical outcomes in invasively mechanically ventilated patients with pulmonary infection. It will also evaluate the safety of IPV in this population and assess changes in lung ventilation using electrical impedance tomography (EIT).\n\nThe main questions it aims to answer are:\n\nDoes adding IPV shorten the duration of invasive mechanical ventilation compared with standard therapy alone? Does IPV improve regional and global lung ventilation? Does IPV improve clinical indicators, including oxygenation, lung mechanics, and pulmonary infection scores? Is IPV safe in mechanically ventilated patients with pulmonary infection?\n\nParticipants will:\n\nReceive either standard therapy alone or standard therapy plus IPV Undergo serial EIT monitoring at predefined time points Receive routine clinical assessments and ventilator parameter monitoring during ICU stay Be followed until successful weaning, discharge, or completion of hospitalization",[28],[28,375,376,377,378],"Intrapulmonary percussion ventilation","mechanical ventilation","electrical impedance tomography","pulmonary infection",{"date":331,"type":38},{"date":381,"type":38},"2026-03-06",{"date":383,"type":22},"2027-05-01",{"name":385,"class":45},"Zhongnan Hospital",{"id":387,"slug":388,"hasResults":12,"nctId":389,"briefTitle":390,"officialTitle":391,"acronym":4,"eligibilityCriteria":392,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":259,"enrollmentInfo":393,"targetDuration":4,"studyType":23,"phases":395,"briefSummary":396,"conditions":397,"keywords":400,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":406,"lastUpdatePostDateStruct":407,"startDateStruct":408,"completionDateStruct":410,"leadSponsor":412,"locationsCount":82},"100637232","phase-3-analysis-of-growth-differentiation-factor-15-gdf-15-mid-regional-proadrenomedullin-mr-proadm-and-persepsin-levels-in-patient-in-acute-coronary-syndrome-patients-with-pneumonia-with-or-without-influenza-vaccination-100637232","NCT07604103","Analysis of Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patient in Acute Coronary Syndrome Patients With Pneumonia, With or Without Influenza Vaccination","Analysis of the Relationship Between Growth Differentiation Factor 15 (GDF-15), Mid Regional proAdrenomedullin (MR proADM), and Persepsin Levels in Patients With Acute Coronary Syndrome With Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) With Influenza Vaccination","Inclusion Criteria:\n\n* Adult male patients (\\\u003C 65 years old).\n* History of being an active smoker.\n* Confirmed diagnosis of Acute Coronary Syndrome (ACS) and Pneumonia based on clinical, laboratory, and radiological criteria.\n* Demonstrated clinical improvement (stabilization) after receiving standard ACS and Pneumonia therapy in the acute intrahospital phase.\n* Willing to undergo all study procedures and sign the Informed Consent form.\n\nExclusion Criteria:\n\n* Presence of absolute contraindications to pneumococcal and influenza vaccination (history of anaphylactic reactions to vaccine components).\n* Patients with malignancies (cancer), systemic autoimmune diseases, or those currently on long-term immunosuppressant therapy.\n* Patients with End-Stage Renal Disease (ESRD) or severe liver dysfunction that could confound inflammatory biomarker values.\n* Patients with persistently unstable hemodynamic conditions or unresolved cardiogenic shock during the acute care phase.\n* Patient death before the observation period (up to post-vaccination) is completed.\n* Patient unilaterally resigns or withdraws consent during the study.\n* Lost to follow-up during scheduled outpatient clinic visits or scheduled follow-up biomarker evaluations.",{"count":394,"type":22},60,[263],"The goal of this observational study is to analyze the relationship between various biomarkers (GDF-15, MR proADM, and Presepsin) in patients with Acute Coronary Syndrome (ACS) who also have Pneumonia and Chronic Obstructive Pulmonary Disease (COPD) and have received Influenza vaccinations.\n\nThe main questions it aims to answer are:\n\n* Is there a significant correlation between the levels of these specific biomarkers and the clinical outcomes or inflammatory status of these patients?\n* How does Influenza vaccinations relate to the levels of these biomarkers in the context of ACS with comorbid respiratory conditions? Researchers will compare the levels of these biomarkers across the participant group to see if they can serve as indicators of the patients' health status or the impact of the vaccinations.\n\nParticipants will:\n\n\\- Undergo clinical assessment for Acute Coronary Syndrome, Pneumonia, and COPD. Provide medical history regarding Influenza vaccination status. Provide blood samples for the measurement of GDF-15, MR proADM, and Presepsin levels.",[398,28,399],"Acute Coronary Syndromes (ACS)","COPD (Chronic Obstructive Pulmonary Disease)",[401,402,403,404,28,405],"GDF-15","MR proADM","Persepsin","Acute coronary syndrome","influenza vaccination","2026-05-16",{"date":331,"type":38},{"date":409,"type":38},"2026-01-01",{"date":411,"type":22},"2026-10-10",{"name":413,"class":45},"University of Brawijaya",{"id":415,"slug":416,"hasResults":12,"nctId":417,"briefTitle":418,"officialTitle":418,"acronym":4,"eligibilityCriteria":419,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":420,"enrollmentInfo":421,"targetDuration":4,"studyType":23,"phases":423,"briefSummary":424,"conditions":425,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":4},"100638894","the-effectiveness-of-different-nebulized-solutions-on-airway-clearance-function-in-patients-with-pneumonia-100638894","NCT07586345","The Effectiveness of Different Nebulized Solutions on Airway Clearance Function in Patients With Pneumonia","Inclusion Criteria:\n\n1. Diagnosed with pneumonia, defined by ICD-10 codes, including:\n\n   J18: Pneumonia, unspecified organism J180: Bronchopneumonia, unspecified organism J181: Lobar pneumonia, unspecified organism J182: Hypostatic pneumonia, unspecified organism J188: Other pneumonia, unspecified organism J189: Pneumonia, unspecified organism\n2. Aged 18-100 years\n3. Clinical respiratory score \\> 3\n4. Patients unable to expectorate sputum spontaneously and requiring assisted suctioning\n\nExclusion Criteria:\n\n1. Diagnosis of influenza-associated pneumonia, defined by ICD-10 codes, including:\n\n   J09X1: Influenza due to identified novel influenza A virus with pneumonia J1001: Influenza due to other identified influenza virus with the same identified influenza viral pneumonia J100: Influenza due to other identified influenza virus with pneumonia\n2. Diagnosis of COVID-19 infection, defined by ICD-10 code:\n\n   U07.1: COVID-19, virus identified\n3. History of chronic obstructive pulmonary disease (COPD) (ICD-10 code: J44)\n4. History of lung cancer or metastatic cancer involving the lungs\n5. Current use of bronchodilators\n6. Patients requiring oral suctioning only\n7. Oxygen therapy with a flow rate \\> 10 L\u002Fmin\n8. Clinical respiratory score \\> 8 (Table 2)","100 Years",{"count":422,"type":22},80,[170],"Pneumonia is a significant global and national health issue, particularly posing a notable threat to elderly population. Accumulation of sputum in pneumonia patients often results in impaired airway clearance, negatively impacting disease management and recovery. Clinically, nebulization therapy is widely employed to facilitate sputum clearance; however, evidence regarding the comparative effectiveness of different nebulized solution concentrations remains limited and inconsistent. Therefore, this study aims to evaluate and compare the clinical effects of nebulized solutions with various osmotic concentrations (3% hypertonic saline, 0.9% normal saline, 0.45% hypotonic saline, and distilled water) on airway clearance in patients with pneumonia. A randomized, double-blind controlled trial design will be used, recruiting 80 patients with pneumonia from a regional teaching hospital in northern Taiwan. Participants will be randomly assigned into four groups, receiving nebulized therapy four times daily over a period of seven days. This study outcome including the length of hospital stay, venous blood gas analysis, routine sputum examination, and arterial oxygen content. The findings of this the study are anticipated to provide evidence-based recommendations for the clinical application of nebulized solutions with different concentrations, aiming to enhance airway clearance efficiency, improve clinical care outcomes for pneumonia patients, and serve as a practical reference for healthcare professionals.",[28,426],"Airway Clearance","2026-05-12",{"date":429,"type":38},"2026-05-14",{"date":431,"type":22},"2026-05-01",{"date":433,"type":22},"2027-12-31",{"name":435,"class":45},"Chen, Yao-Hsiang",{"id":437,"slug":438,"hasResults":12,"nctId":439,"briefTitle":440,"officialTitle":441,"acronym":4,"eligibilityCriteria":442,"healthyVolunteers":12,"sex":17,"minAge":259,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":456},"100474057","a-study-to-learn-about-how-20-valent-pneumococcal-conjugate-vaccine-works-in-a-real-world-setting-100474057","NCT05452941","A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","A Phase 4 Study Using a Test-Negative Design to Evaluate the Effectiveness of a 20-valent Pneumococcal Conjugate Vaccine Against Vaccine-type Radiologically-confirmed Community-acquired Pneumonia in Adults >\u002F= 65 Years of Age","Inclusion Criteria:\n\n1. Male or female participants ≥65 years of age.\n2. Hospitalized participant with physician clinical suspicion of CAP with the presence of ≥2 of the following 10 clinical signs or symptoms:\n\n   * fever (oral temperature \\>38.0°C\u002F100.4°F or tympanic temperature \\>38.5°C\u002F101.2°F),\n   * hypothermia (\\\u003C35.5°C\u002F95.9°F measured by a healthcare provider)\n   * chills or rigors,\n   * pleuritic chest pain,\n   * new or worsening cough,\n   * sputum production,\n   * dyspnea (shortness of breath),\n   * tachypnea (respiratory rate \\>20\u002Fmin),\n   * malaise, or\n   * abnormal auscultatory findings suggestive of pneumonia (rales or evidence of pulmonary consolidation including dullness on percussion, bronchial breath sounds, or egophony).\n3. Has a radiographic finding that is consistent with pneumonia (e.g., pleural effusion, increased pulmonary density due to infection, the presence of alveolar infiltrates \\[multi-lobar, lobar, or segmental\\] containing air bronchograms).\n4. Capable of giving signed informed consent\n\nExclusion Criteria:\n\n1. Any participant who develops signs and symptoms of pneumonia after being hospitalized for ≥48 hours (either at the study site, another transferring hospital, or a combination of these).\n2. Received any pneumococcal vaccine ≤30 days prior to enrollment.\n3. Unable to provide urine specimen (e.g. anuric).\n4. Previous enrollment in the study within the past 30 days.",{"count":444,"type":22},12500,"The purpose of this study is to learn about how well the 20-valent pneumococcal conjugate vaccine (20vPnC) works against radiologically-confirmed community-acquired pneumonia (RAD+CAP) due to the 7 new serotypes (types of a bacteria called Streptococcus pneumoniae that cause pneumonia) included in 20vPnC vaccine.\n\nThis study is seeking participants who:\n\n* are male or female ≥65 years of age.\n* are hospitalized with physician suspicion of community acquired pneumonia (CAP).\n* have pneumonia confirmed with imaging like a chest x-ray\n\nParticipants will be asked to provide demographic and medical history information, and to provide a urine sample that will be used to test for pneumonia caused by specific strains of a bacteria called Streptococcus pneumoniae. We will compare the proportion of participants who have pneumonia caused by specific strains of the bacteria Streptococcus pneumoniae and were previously vaccinated with 20vPnC with the proportion of participants who have pneumonia caused by something other than vaccine type Streptococcus pneumoniae and have been vaccinated with 20vPnC. Participants will actively take part in the study for about 1-2 days. Information on participant's illness and hospitalization details will be collected through day 30 of their hospitalization through medical chart review.",[28],"2026-05-07",{"date":449,"type":38},"2026-05-11",{"date":451,"type":38},"2022-10-27",{"date":453,"type":22},"2027-06-04",{"name":455,"class":158},"Pfizer",54,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":52,"sex":17,"minAge":90,"maxAge":420,"enrollmentInfo":464,"targetDuration":466,"studyType":57,"phases":4,"briefSummary":467,"conditions":468,"keywords":475,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":481,"startDateStruct":482,"completionDateStruct":484,"leadSponsor":486,"locationsCount":82},"100465142","emergency-pwas-in-respiratory-infectious-disease-100465142","NCT05336851","Emergency PWAS in Respiratory Infectious Disease","Emergency PanorOmic Wide Association Study in Respiratory Infectious Disease (ePWAS-RID)","Inclusion Criteria:\n\nPatients eligible for enrolment include:\n\nWith reference to previous inclusion criteria are:\n\n* Adults ≥18 years of age; AND\n* Suspected, acute, community-acquired, respiratory, infectious disease (scaRID)\\*; AND\n* Informed consent.\n\nNote: scaRID is defined according to ALL three criteria:\n\n1. Community acquired (not hospitalised for \\\u003C28 days); AND\n2. Acute infection (defined as symptom onset \\\u003C8 days and any ONE of reported fever or chills or aural temperature \\>37.5°C or hypothermia or leucocytosis or leucopaenia or new altered mental status); AND\n3. Probable respiratory infection - According to any ONE of:\n\n   1. new cough or new sputum production or\n   2. chest pain or\n   3. dyspnoea or\n   4. tachypnoea or\n   5. abnormal lung examination or\n   6. respiratory failure; or\n   7. physician's judgment (presenting with systemic or gastrointestinal symptoms).\n\nControl subjects will be drawn from two groups:\n\n* The worried well - adult patients with a National Early Warning Score (NEWS) \\\u003C3 and a temperature \\\u003C37.5°C.\n* Relatives or accompanying friends with no acute illness.\n\nExclusion Criteria:\n\n* Refusal of consent;\n* Recent hospitalisation (\\\u003C28 days);\n* Enrolled in another clinical trial\n* Cellulitis;\n* Skin or orthopaedic infections;\n* Urinary tract infection;\n* Acute abdominal sepsis;\n* Sexual transmitted disease;\n* Human immunodeficiency virus (HIV) infection;\n* Immunocompromised\u002Fpotential neutropenic fever;\n* Solid organ or haematopoietic stem-cell transplant within the previous 90 days;\n* Active graft-versus-host disease or bronchiolitis obliterans;\n* Severe traveller's disease requiring urgent hospitalisation and management including malaria, dengue, typhoid and other rickettsial diseases;\n* Stroke;\n* Toxidrome;\n* Non-organic acute psychosis.",{"count":465,"type":22},2000,"1 Year","Develop an emergency PanorOmics Wide Association Study (ePWAS) for the early, rapid biological and pathophysiological characterisation of known and novel Infectious Diseases in adult patients presenting to emergency departments with suspected, acute, community-acquired respiratory infectious disease (scaRID).\n\nPhase 1\n\n1. Develop an ED-ID biobank (named ePWAS-RID). Phase 2\n2. Targeted research for the discovery of novel diagnostics, prognostics and therapeutics",[469,470,471,472,473,474,28,228],"Viral Infections","Bacterial Infections","Fungal Infections","Mixed Infection","Mycobacterium Infection","Infection of Uncertain Aetiology",[476,477,478,479,480],"Biobank","Diagnostics and Prognostics","Emergency Medicine","Multiomics and Panoromics","Respiratory Infectious Disease",{"date":427,"type":38},{"date":483,"type":38},"2023-04-11",{"date":485,"type":22},"2028-05-01",{"name":487,"class":45},"The University of Hong Kong",{"id":489,"slug":490,"hasResults":12,"nctId":491,"briefTitle":492,"officialTitle":492,"acronym":4,"eligibilityCriteria":493,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":494,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":496,"conditions":497,"keywords":498,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":500,"startDateStruct":502,"completionDateStruct":503,"leadSponsor":504,"locationsCount":82},"100639655","a-retrospective-study-on-clinical-characteristics-and-outcomes-of-patients-with-pneumonia-100639655","NCT07574866","A Retrospective Study on Clinical Characteristics and Outcomes of Patients With Pneumonia","Inclusion Criteria:\n\n1. Age ≥ 18 years old;\n2. Meet the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging);\n3. Have a positive result from pathogen testing;\n4. Time from onset to admission ≤ 72 hours (to ensure being in the acute phase of the disease);\n5. Sign a written informed consent form.\n\n   Inclusion criteria for the severe group:\n\n   A diagnosis of \"severe pneumonia\" can be made if one of the main criteria or ≥ 3 of the secondary criteria are met.\n\n   Main criteria:\n\n   ① Tracheal intubation requiring mechanical ventilation\n\n   ② Need for vasoactive drugs after active fluid resuscitation for septic shock\n\n   Secondary criteria:\n   * Respiratory rate ≥ 30 breaths\u002Fmin\n\n     * PaO₂\u002FFiO₂ ≤ 250 mm Hg\n\n       * Multiple lobe infiltrates\n\n         * Confusion and\u002For disorientation ⑤ Blood urea nitrogen ≥ 20 mg\u002FdL\n\n           ⑥ Leukopenia (WBC \\\u003C 4×10⁹\u002FL)\n           * Thrombocytopenia (PLT \\\u003C 100×10⁹\u002FL)\n\n             * Decreased body temperature (central body temperature \\\u003C 36 ℃) ⑨ Hypotension requiring fluid resuscitation\n\n   Exclusion Criteria:\n   * 1\\) Patients with severely lacking medical records;\n\n2\\) Those whose main manifestations are other non-infectious diseases (such as pulmonary edema, lung cancer, pulmonary embolism, etc.); 3) Those whose main diagnosis is active pulmonary tuberculosis, non-infectious interstitial lung disease, etc.; 4) Patients considered not applicable by the researchers.",{"count":495,"type":22},500,"Retrospective Analysis of Clinical Characteristics and Prognostic Factors in Hospitalized Pneumonia Patients from April 2023 to April 2026. Background: Pneumonia remains the leading cause of death from infectious diseases in adults worldwide, with an increasingly severe disease burden exacerbated by population aging and the frequent emergence of drug-resistant bacteria; in China, severe pneumonia accounts for a striking 13.58% to 20.05% of hospitalized cases. In recent years, shifts in the pathogen spectrum (e.g., COVID-19, influenza A) and patient demographic characteristics have posed new challenges for clinical management. However, existing studies mostly focus on single pathogens or specific populations (e.g., ICU patients), lacking systematic analyses of the full-disease course characteristics of general hospitalized pneumonia patients. Furthermore, in the post-pandemic era, the clinical phenotypes, treatment responses, and prognostic factors of pneumonia may have evolved, necessitating evidence-based support from real-world data. This study aims to conduct a retrospective analysis to clarify the epidemiological characteristics, etiological distribution, and prognostic factors influencing current hospitalized pneumonia patients, thereby providing a basis for optimizing diagnosis and treatment strategies.",[28],[175],"2026-05-05",{"date":501,"type":38},"2026-05-08",{"date":280,"type":22},{"date":335,"type":22},{"name":505,"class":45},"Zhonghao Fang",{"id":507,"slug":508,"hasResults":12,"nctId":509,"briefTitle":510,"officialTitle":511,"acronym":512,"eligibilityCriteria":513,"healthyVolunteers":52,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":514,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":516,"conditions":517,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":499,"lastUpdatePostDateStruct":521,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":82},"100625752","a-study-measuring-markers-of-airway-inflammation-in-breath-samples-from-people-with-respiratory-diseases-and-healthy-volunteers-100625752","NCT07426718","A Study Measuring Markers of Airway Inflammation in Breath Samples From People With Respiratory Diseases and Healthy Volunteers.","An Expanded inVestigation of Inflammacheck™ to Measure Exhaled Breath CondensaTe Hydrogen perOxide in RespiratorY Conditions A Cross-sectional, Observational Study Comparing Exhaled Breath Biomarkers Across Respiratory Diseases and Healthy Volunteers.","VICTORY 2","Inclusion Criteria:\n\n\\- 1. Age: Adults aged ≥18 years. 2. Consent: Willing and able to provide written informed consent (prospective participants only).\n\n3\\. Clinical status: Belong to one of the defined diagnostic categories listed below:\n\n1. Group A: Lung cancer confirmed by multidisciplinary team (MDT) diagnosis.\n2. Group B: Suspected lung cancer (biopsy negative or awaiting further investigation).\n3. Group C: Pneumonia (radiologically or clinically confirmed).\n4. Group D: Non-malignant airways diseases (asthma or COPD).\n5. Group E: Other non-malignant respiratory diseases (interstitial lung disease, bronchiectasis, breathing pattern disorder).\n6. Group F: Healthy controls with no known respiratory disease. 4. Clinical documentation: Availability of relevant diagnostic and demographic data to confirm disease classification (for retrospective participants).\n\n   5\\. Previous participation: Individuals previously enrolled in the VICTORY or ExPeL studies may be included for retrospective data integration.\n\n   6\\. Willing and able to perform a breath test using the Inflammacheck® device. 7. Willing to allow access to relevant clinical data and imaging results 8. Be able to understand and communicate in English with or without the need for a translator, to ensure informed consent and comprehension of study procedures\n\n   Exclusion Criteria:\n   * 1\\. Active respiratory infection (e.g., tuberculosis, bronchopneumonia) other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     2\\. History of major thoracic surgery or lung resection within the previous six months.\n\n     3\\. Current or recent chemotherapy or radiotherapy for lung cancer at the time of breath sampling (except for retrospective confirmed cancer cases where data were collected pre-treatment).\n\n     4\\. Severe cognitive impairment, communication barriers, or any condition preventing informed consent or compliance with study procedures.\n\n     5\\. Pregnancy or breastfeeding. 6. Active use of cannabis or recreational drugs known to alter exhaled breath composition.\n\n     7\\. Current active tobacco smoking within the past 12 hours prior to breath collection will be an exclusion criterion, as will the use of vaping or e-cigarettes within this period, to prevent contamination of exhaled breath samples 8. Participants who have taken systemic antibiotics or commenced a new course of oral or inhaled corticosteroids within the preceding two weeks will also be excluded, as these may transiently alter inflammatory biomarkers in exhaled breath (this is not applicable to participants with pneumonia). Stable use of maintenance inhaled corticosteroids in patients with chronic respiratory conditions (e.g., asthma, COPD) will be permitted, provided dosing has remained unchanged for at least four weeks prior to sampling.\n\n     9\\. Any condition that, in the opinion of the investigator, could compromise participant safety or the integrity of the data.\n\n     10\\. Unable or unwilling to provide informed consent. 11. Unable to complete the breath test due to physical or cognitive limitations.\n\n     12\\. Currently participating in another interventional clinical trial that may confound breath biomarker data.\n\n     13\\. Received systemic treatment for lung cancer prior to breath sampling (for the lung cancer group only).\n\n     14\\. History of any active cancer within the past 12 months (excluding basal cell carcinoma of the skin or cervical carcinoma in situ), except for those in the confirmed lung cancer group.\n\n     15\\. They have any active respiratory infection other than pneumonia (e.g., tuberculosis) at the time of breath sampling.\n\n     16\\. They have undergone a bronchoscopy or invasive respiratory procedure within the past 48 hours, due to the potential for artefacts in breath data.\n\n     17\\. Pneumonia with concurrent lung cancer, thoracic malignancy or lung fibrosis. Pneumonia with co-existent asthma or COPD can be included at discretion of the PI.",{"count":515,"type":22},140,"Lung cancer remains the leading cause of cancer-related death in the UK, with over 35,000 deaths annually and most cases diagnosed at a late stage. Current screening programmes using low-dose CT scans target only high-risk individuals, missing around 30% of lung cancer cases, including many women and never-smokers. There is no simple, non-invasive tool to help triage patients with persistent respiratory symptoms who fall outside formal screening criteria. Inflammacheck® measures hydrogen peroxide and other breath biomarkers linked to airway inflammation and oxidative stress. Preliminary studies (VICTORY and ExPeL) have shown strong diagnostic performance for distinguishing lung cancer from other respiratory conditions. VICTORY 2 aims to validate and refine the AI model supporting Inflammacheck®, enabling accurate, rapid, and affordable triage for suspected lung cancer in NHS settings.",[518,519,520,28],"Lung Cancer (Diagnosis)","Lung Cancer (Suspected or Confirmed)","Healthy",{"date":501,"type":38},{"date":523,"type":38},"2026-03-05",{"date":525,"type":22},"2026-12-30",{"name":527,"class":528},"Portsmouth Hospitals NHS Trust","OTHER_GOV",{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":533,"acronym":4,"eligibilityCriteria":534,"healthyVolunteers":52,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":535,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":536,"conditions":537,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":540,"lastUpdatePostDateStruct":541,"startDateStruct":542,"completionDateStruct":544,"leadSponsor":546,"locationsCount":82},"100442419","hyperpolarized-129-xenon-imaging-in-adult-hematopoietic-cell-transplant-recipients-with-pulmonary-impairment-100442419","NCT05041140","Hyperpolarized 129-Xenon Imaging in Adult Hematopoietic Cell Transplant Recipients With Pulmonary Impairment","Inclusion Criteria:\n\n\\- Allo-HCT recipients who are at least 18 years of age and have BOS (n=10 patients), BOS 0p (n = 10 patients), or cGVHD of a non-lung organ without evidence of pulmonary impairment (n = 5 patients).\n\nHealthy Cohort - Inclusion Criteria:\n\nWe will perform only XeMRI imaging on 10 healthy adult (18 years and older) volunteers with no medical issues for technical calibration of the XeMRI technology. Members of the study team may serve as healthy volunteers if they have no prior history of lung disease. These data will not be included as part of the analysis.\n\nExclusion Criteria:\n\n1. Participants unable to follow up at MD Anderson for routine clinical care\n2. Inability or unwillingness to give informed consent\n3. Relapsed disease or life expectancy less than 6 months at time of enrollment\n4. Severe claustrophobia precluding MRI imaging\n5. Active pulmonary infection\n6. Pregnant women",{"count":7,"type":22},"This study is designed to measure the correlation of hyperpolarized 129-Xe magnetic resonance imaging (129-XeMRI) in allogeneic hematopoietic cell transplant (allo-HCT) recipients at MD Anderson Cancer Center (MDACC) who develop bronchiolitis obliterans syndrome (BOS) or BOS stage 0p (pulmonary impairment not meeting the definition for BOS, defined below) and controls with chronic graft-versus-host disease (cGVHD).\n\nThe primary objective of the study is to correlate 129-Xenon measures of ventilation, gas exchange, and pulmonary circulation with spirometric and quantitative CT measurements.\n\nA secondary objective is to determine whether measurement of 129-Xe MRI characteristics in patients with BOS stage 0p can predict BOS progression 6 months after enrollment.",[538,28,539],"Pulmonary","Hematopoietic System--Cancer","2026-04-29",{"date":499,"type":38},{"date":543,"type":38},"2024-08-14",{"date":545,"type":22},"2027-07-20",{"name":547,"class":45},"M.D. Anderson Cancer Center",{"id":549,"slug":550,"hasResults":12,"nctId":551,"briefTitle":552,"officialTitle":552,"acronym":4,"eligibilityCriteria":553,"healthyVolunteers":12,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":554,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":556,"conditions":557,"keywords":559,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":562,"startDateStruct":563,"completionDateStruct":564,"leadSponsor":566,"locationsCount":82},"100636609","a-prospective-observational-cohort-study-protocol-for-disease-severity-stratification-and-prognosis-assessment-in-patients-with-pneumonia-100636609","NCT07567911","A Prospective Observational Cohort Study Protocol for Disease Severity Stratification and Prognosis Assessment in Patients With Pneumonia","1. Inclusion and Exclusion Criteria for Pneumonia Patients 1.1 Inclusion Criteria 1) Age ≥ 18 years old; 2) Meeting the diagnostic criteria for pneumonia (acute onset + new infiltrates on imaging); 3) Time from onset to admission ≤ 72 hours; 4) Signed written informed consent. 1.1.1 Inclusion Criteria for Severe Pneumonia Patients A diagnosis of \"severe pneumonia\" can be made if one of the main criteria or ≥ 3 of the secondary criteria are met.\n\n   Main Criteria:\n\n   ① Requires mechanical ventilation with tracheal intubation\n\n   ② Requires vasopressor drugs after aggressive fluid resuscitation for septic shock\n\n   Secondary Criteria:\n   * Respiratory rate ≥ 30 breaths\u002Fmin\n\n     * PaO₂\u002FFiO₂ ≤ 250 mm Hg\n\n       * Multiple lobe infiltrates\n\n         * Confusion and\u002For disorientation\n\n           ⑤ Blood urea nitrogen ≥ 20 mg\u002FdL\n\n           ⑥ Leukopenia (WBC \\\u003C 4×10⁹\u002FL)\n\n           ⑦ Thrombocytopenia (PLT \\\u003C 100×10⁹\u002FL)\n\n           ⑧ Decreased body temperature (central body temperature \\\u003C 36 ℃)\n\n           ⑨ Hypotension requiring fluid resuscitation 1.2 Exclusion Criteria\n           1. End-stage diseases (such as expected survival \\\u003C 48 hours);\n           2. Long-term immunosuppressive therapy (prednisone \\> 20mg\u002Fd for more than 3 weeks, or neutropenia after chemotherapy);\n           3. Pregnant or lactating women. 2. Inclusion and Exclusion Criteria for Patients with Suspected Infection but Negative Pathogen Testing 2.1 Inclusion Criteria\n\n           \u003C!-- -->\n\n           1. Age ≥ 18 years old;\n           2. Having infection-related symptoms or signs (such as fever, cough, sputum production, elevated white blood cells, etc.), clinically suspected of pneumonia;\n           3. All pathogen tests are negative within 3 days after admission;\n           4. Time from onset to admission ≤ 72 hours;\n           5. Signed written informed consent. 2.2 Exclusion Criteria\n\n           \u003C!-- -->\n\n           1. End-stage diseases (such as expected survival \\\u003C 48 hours);\n           2. Long-term immunosuppressive therapy;\n           3. Pregnant or lactating women;",{"count":555,"type":22},2700,"This is a prospective, multicenter observational cohort study involving approximately 2,700 patients, designed to delineate the natural history of pneumonia by tracking the complete clinical course and dynamic multi-omics evolution from the acute phase to recovery; the study aims to quantify severe conversion rates and mortality by comparing baseline characteristics, pathogen distribution, and immune response trajectories between severe and non-severe groups, ultimately revealing the underlying molecular mechanisms of disease progression and optimizing clinical risk stratification strategies.",[558,28],"Severe Pneumonia",[175,560],"severe pneumonia","2026-04-28",{"date":499,"type":38},{"date":431,"type":22},{"date":565,"type":22},"2028-05-28",{"name":505,"class":45},{"id":568,"slug":569,"hasResults":12,"nctId":570,"briefTitle":571,"officialTitle":572,"acronym":4,"eligibilityCriteria":573,"healthyVolunteers":12,"sex":17,"minAge":466,"maxAge":574,"enrollmentInfo":575,"targetDuration":4,"studyType":23,"phases":577,"briefSummary":578,"conditions":579,"keywords":582,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":561,"lastUpdatePostDateStruct":587,"startDateStruct":588,"completionDateStruct":590,"leadSponsor":592,"locationsCount":159},"100636237","effect-of-high-flow-nasal-cannula-oxygen-therapy-on-hypoxemia-in-pediatric-sedated-bronchoscopy-100636237","NCT07563075","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy","Effect of High-Flow Nasal Cannula Oxygen Therapy on Hypoxemia in Pediatric Sedated Bronchoscopy: A Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* 1 year ≤ age ≤ 6 years,\n* Weight ≥ 10 kg,\n* Undergoing elective sedated bronchoscopy,\n* Expected procedure duration ≤ 45 minutes,\n* Written informed consent obtained from the subject's legal guardian.\n\nExclusion Criteria:\n\n* preoperative SpO₂ \\\u003C 95% on room air,\n* Already sedated and tracheally intubated,\n* Known history of pneumothorax, known congenital or acquired upper airway abnormalities (e.g., nasopharyngeal structural anomalies), or history of difficult airway,\n* Coagulation disorders or predisposition to oral\u002Fnasal bleeding, mucosal injury, or space-occupying lesions,\n* Severe cardiac insufficiency (\\\u003C 4 METs), severe renal insufficiency (requiring dialysis), diagnosed severe hepatic insufficiency, Increased intracranial pressure, or ASA classification ≥ IV,\n* Allergy to propofol or sufentanil,\n* Multiple traumatic injuries,\n* Current participation in another clinical trial,\n* Other conditions deemed unsuitable by the investigator.","6 Years",{"count":576,"type":22},430,[170],"Due to children's lower oxygen reserves and higher oxygen consumption, sedation can easily lead to respiratory adverse events such as hypoxemia. It has been reported that the incidence of hypoxemia during pediatric bronchoscopy is high, highlighting that hypoxemia in pediatric painless bronchoscopy is an urgent problem requiring a solution. High-flow nasal cannula (HFNC) oxygen therapy delivers heated and humidified breathing gas with a precisely controllable oxygen concentration, at flow rates exceeding the patient's peak inspiratory flow, directly via unsealed nasal prongs. It is a simple, comfortable, effective, and non-invasive respiratory support method that has been widely adopted in clinical practice. However, the effectiveness of HFNC in pediatric sedation remains unclear. Therefore, this multicenter randomized controlled trial aims to evaluate whether HFNC can effectively reduce the occurrence of hypoxemia during sedated bronchoscopy in pediatric patients.",[580,28,581],"Hypoxemia","Pulmonary Neoplasm",[583,580,584,585,586],"Bronchoscopy","Sedation","Pediatric","High-flow nasal cannula",{"date":431,"type":38},{"date":589,"type":22},"2026-04-01",{"date":591,"type":22},"2027-03-31",{"name":593,"class":45},"Zhejiang University",{"id":595,"slug":596,"hasResults":12,"nctId":597,"briefTitle":598,"officialTitle":599,"acronym":4,"eligibilityCriteria":600,"healthyVolunteers":52,"sex":17,"minAge":90,"maxAge":4,"enrollmentInfo":601,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":603,"conditions":604,"keywords":4,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":611,"lastUpdatePostDateStruct":612,"startDateStruct":614,"completionDateStruct":616,"leadSponsor":618,"locationsCount":82},"100591664","validation-and-clinical-utility-of-the-lung-sliding-index-lsi-for-differentiating-pulmonary-diseases-100591664","NCT06983366","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases","Validation and Clinical Utility of the Lung Sliding Index (LSI) for Differentiating Pulmonary Diseases: A Prospective Case-Control Study","Inclusion Criteria:\n\n* Age 18 years and older.\n* Diagnosed with one of the specified pulmonary diseases, or a healthy control\n* Able to provide written informed consent\n\nExclusion Criteria:\n\n* Inability to tolerate or undergo a lung ultrasound\n* Extensive chest wall pathology precluding assessment\n* Unscorable \\>2 zones per protocol\n* Withdrawal of consent\n* Mechanically-ventilated patients",{"count":602,"type":22},700,"This upcoming case-control study aims to confirm the Lung Sliding Index (LSI), a new ultrasound score that measures how well the pleura moves, in various lung diseases. The study will check how well the LSI can tell apart different lung diseases (like pneumothorax, interstitial lung disease, COPD, pneumonia, and pulmonary edema), how it relates to signs of disease severity, and how consistent the results are between different operators who have received the same training. Secondary objectives include assessing patient and operator satisfaction and feasibility using validated Likert scales.",[605,606,607,608,28,609,610],"COPD","ILD","Bronchiectasis","Pneumothorax","Pleural Effusion Disorder","Pulmonary Oedema","2026-04-26",{"date":613,"type":38},"2026-04-30",{"date":615,"type":38},"2025-05-30",{"date":617,"type":22},"2026-08-01",{"name":619,"class":45},"Assiut University",{"id":621,"slug":622,"hasResults":12,"nctId":623,"briefTitle":624,"officialTitle":625,"acronym":626,"eligibilityCriteria":627,"healthyVolunteers":12,"sex":17,"minAge":628,"maxAge":90,"enrollmentInfo":629,"targetDuration":4,"studyType":23,"phases":631,"briefSummary":632,"conditions":633,"keywords":635,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":637,"lastUpdatePostDateStruct":638,"startDateStruct":639,"completionDateStruct":641,"leadSponsor":643,"locationsCount":645},"100600629","promoting-optimal-treatment-for-community-acquired-pneumonia-in-emergency-rooms-100600629","NCT07099976","PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms","PromotIng Optimal Treatment for Community-acquired PNeumonia in EmErgency Rooms (PIONEERS): a Multicentre, Randomized, Open-labelled, Controlled, Clinical Trial","PIONEERS","Inclusion Criteria:\n\nChildren aged 6 month to 18 years presenting to the Emergency Department who are diagnosed with CAP and are well enough to be discharged home (i.e. 'non-severe' CAP) will be eligible. They must have a fever (on exam or by history) and at least one of:\n\n* Tachypnoea measured at triage (\\>60 bpm for age \\\u003C1, \\>50 for 1-2 years of age, \\>40bpm for 2-4 years of age, and \\>30bpm for \\>4 years of age)\n* Cough on exam or by history\n* Increased work of breathing on exam\n* Auscultatory finding (focal crackles, bronchial breathing, etc.) consistent with CAP\n\nExclusion Criteria:\n\nChildren will be excluded if they have any of the following\n\n* Cystic Fibrosis\n* Anatomic Lung Disease\n* Bronchiectasis\n* Chronic Lung Disease requiring home oxygen or home ventilation\n* Congenital heart Disease (requiring specific medical treatment or with exercise restrictions),\n* History of repeated aspiration\u002Fvelopharyngeal incompetence\n* Malignancy\n* Immunodeficiency (primary, acquired or iatrogenic)\n* Pneumonia previously (clinically) diagnosed within the past month (that was presumed to have resolved prior to the episode prompting the current visit to the ED)\n* Lung abscess within the past 6 months\n* Children who present with ongoing fever after 4 days of amoxicillin, cefprozil, cefuroxime, levofloxacin, moxifloxacin or doxycycline are not eligible; as this duration of therapy with these drugs would normally be sufficient to treat bacterial CAP, a different approach would be required (ie. the care pathway as written might not be appropriate).\n* Children will not be eligible to participate more than once","6 Months",{"count":630,"type":22},698,[170],"In North America, up to 5% of preschoolers develop community-acquired pneumonia (CAP) every year. Pneumonia is the second-leading reason for paediatric hospitalization in both Canada and the US; approximately 20% of children hospitalized with CAP may need intensive care, which can result in significant morbidity. Given this burden of disease, it is critical that CAP is managed appropriately. Specific therapy for CAP is dependent on microbiologic aetiology, as bacterial disease will improve with antibiotic treatment.",[634,28],"Community-Acquired Pneumonia (CAP)",[28,636],"Antibiotics","2026-04-23",{"date":540,"type":38},{"date":640,"type":38},"2026-04-15",{"date":642,"type":22},"2030-05-15",{"name":644,"class":45},"Jeffrey Pernica",6,{"id":647,"slug":648,"hasResults":12,"nctId":649,"briefTitle":650,"officialTitle":651,"acronym":4,"eligibilityCriteria":652,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":653,"targetDuration":4,"studyType":57,"phases":4,"briefSummary":655,"conditions":656,"keywords":660,"overallStatus":73,"whyStopped":4,"lastUpdateSubmitDate":662,"lastUpdatePostDateStruct":663,"startDateStruct":664,"completionDateStruct":666,"leadSponsor":668,"locationsCount":82},"100559651","monitoring-of-antimicrobial-resistance-based-on-metagenomics-analyses-in-pneumonia-patients-100559651","NCT06566898","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients","Monitoring of Antimicrobial Resistance Based on Metagenomics Analyses in Pneumonia Patients: a Genomic Epidemiology Study","Inclusion Criteria:\n\n* Patients clinically diagnosed as severe pneumonia and mild pneumonia are diagnosed according to the Guidelines for the diagnosis and Treatment of community-acquired pneumonia in Adults (2019 edition) formulated by the American Thoracic Society (ATS) and the Infectious Diseases Society of America (IDSA), who meet 1 of the following major criteria or ≥3 minor criteria can be diagnosed. The diagnostic criteria for severe and mild pneumonia in children were adopted by the British Thoracic Society (BTS) in 2011.\n* Clinical examination was performed, and there was biospecimen (nasopharyngeal swab, oropharyngeal swab, bronchoalveolar lavage fluid, sputum, blood, hydrothorax, lung tissue) remaining in the clinical microbiological examination.\n\nExclusion Criteria:\n\n* Patients whose biological samples may be contaminated;\n* Patients with alveolar lavage fluid or hydrothorax volume less than 200μl.",{"count":654,"type":22},800,"Monitoring of antimicrobial resistance (AMR) based on metagenomics analyses in pneumonia patients is critical for optimizing clinical diagnosis and treatment and improving clinical prognosis. This study is designed to ask the following key questions:\n\n1. What is the microbiome maps of patients with severe pneumonia and mild pneumonia ?\n2. How many pathogen resistance genes are carrying in severe pneumonia and mild pneumonia ?\n3. What is the genetic diversity of key pathogens detected in severe pneumonia and mild pneumonia during 2019-2025?",[28,657,658,659],"Next-generation Sequencing","Microbiome","Antimicrobial Resistance",[28,661,658,659],"Next-generation sequencing","2026-04-21",{"date":637,"type":38},{"date":665,"type":38},"2024-08-01",{"date":667,"type":22},"2026-09-30",{"name":669,"class":45},"Shanghai General Hospital, China"]